Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 14/20 | 0.53 |
| ▸ | THRA | P10827 | 13/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25528683 | 0.93 | THRB (0.47) | THRBTHRAMAOAMAOB | |
| SCHEMBL23003762 | 0.91 | THRB (0.66) | THRBTHRA | |
| SCHEMBL25528612 | 0.88 | THRA (0.53) | THRBTHRAMAOAMAOBMEN1 | |
| SCHEMBL23003721 | 0.84 | THRB (0.57) | THRBTHRA | |
| SCHEMBL281956 | 0.83 | THRB (0.77) | THRBTHRA | |
| SCHEMBL23003730 | 0.82 | THRB (0.47) | THRBTHRAMEN1KMT2AALDH1A1 | |
| SCHEMBL23003624 | 0.82 | THRB (0.45) | THRBTHRAALDH1A1MAPT | |
| SCHEMBL23003790 | 0.81 | THRB (0.45) | THRBTHRAMEN1HTTKMT2A | |
| SCHEMBL29373597 | 0.81 | THRB (0.69) | THRBTHRA | |
| SCHEMBL3341367 | 0.81 | THRB (0.69) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667606-B2 | Thyromimetics | TPO, TSHR, TTR | THRB 9/4885THRA 4/4885MAOA 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.